U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C11H14N2O2
Molecular Weight 206.2411
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENETURIDE

SMILES

CCC(C(=O)NC(N)=O)C1=CC=CC=C1

InChI

InChIKey=AJOQSQHYDOFIOX-UHFFFAOYSA-N
InChI=1S/C11H14N2O2/c1-2-9(10(14)13-11(12)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H3,12,13,14,15)

HIDE SMILES / InChI

Description

Pheneturide ((brand names Benuride, Deturid, Pheneturid, Septotence, Trinuride), a decarboxylation product of phenobarbital, has been shown to be an effective drug against seizures, and in particular psychomotor seizures. It has being marketed in Europe, including in Poland, Spain, and the United Kingdom. Pheneturide is supplied in compressed tablets each containing 200 mg. of the drug. It can also be obtained in compound tablets (" trinuride ') each of which contain 200 mg. of pheneturide, 40 mg. of diphenylhydantoin, and 15 mg. of phenobarbitone. Animal experiments have shown that pheneturide protects against drug-induced and electrically induced convulsions.

CNS Activity

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Laburide

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended daily dose of the drug in adults is 600-800 mg.,
Route of Administration: Oral
In Vitro Use Guide
Unknown